Menu Laterale Completo
🇮🇹 ITA 🇬🇧 ENG
× 📱 DOWNLOAD APP OUR SERVICE

🌎CURIS INC. MILESTONES AND DATA

🌎CURIS INC. MILESTONES AND DATA

Day: 08 | Time: 11:35:00.000Z Curis Inc., a biotechnology company developing innovative therapies to slow or prevent cancer progression and prolong life, has several significant clinical trial milestones expected by the end of this year. Their lead drug candidate is Emavusertib, a first-in-class IRAK4 inhibitor in Phase I/II clinical trials for leukemia and lymphoma. According to the company, initial Phase I/II clinical data of Emavusertib has demonstrated anti-tumor activity as a single agent in acute myeloid leukemia and non-Hodgkin lymphoma, with potential applications in combination with standard care as well. The company is also evaluating the use of Emavusertib in combination with Ibrutinib for non-Hodgkin lymphoma, with updated data expected by 2024. Currently, the company does not generate revenue from direct product sales, but recognizes royalty revenue tied to the sales of Genentech/Roche's Erivedge. Curis closed the first quarter of 2024 with a net loss of $11.9 million and a cash position of $40.7 million.